

## REFERENCES

EMA Public Statement - Review of recombinant Factor VIII (FVIII) products and inhibitor development. EMA website: <http://www.emea.eu.int/pdfs/human/press/pus/33131605en.pdf>; 2005

Peerlinck et al.: A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate. *Thromb Haemost* 69: 115; 1993

Peerlinck et al.: Factor VIII inhibitors in previously treated haemophilia A patients with a double virus-inactivated plasma derived factor VIII concentrate. *Thromb Haemost* 77: 88; 1997

Rosendaal et al.: A sudden increase in Factor VIII inhibitor development in multitransfused haemophilia A patients in the Netherlands. *Blood* 81: 2180; 1993

## LIST OF PARTICIPANTS

### EXTERNAL EXPERTS

**J. Astermark**

University Hospital Malmö, Department for Hematology and Coagulation Disorders

**G. Auerswald**

Professor-Hess-Kinderklinik, Germany

**J. Goudemand**

Hôpital Cardiologique, Laboratoire d'Hématologie B, France

**B. Haschberger**

Paul-Ehrlich Institut, Germany

**C. R.M. Hay**

Manchester Haemophilia Comprehensive Care Centre, United Kingdom

**J. Ingerslev**

Haemophilia and Thrombosis Centre, Denmark

**A. Kallas**

University of Tartu, Institute of Cell and Molecular Biology, Estonia

**R. Lassila**

HUS, Department of Coagulation Disorders, Division of Hematology, Finland

**C. Lee**

United Kingdom

**P.M. Mannucci**

A. Bianchi Bonomi Hemophilia and Thrombosis Centre, Italy

**P. Meijer**

ECAT Foundation, The Netherlands

**S. Raut**

National Institute for Biological Standards and Control, United Kingdom

**J-M. Saint-Remy**

Centre for Molecular & Vascular Biology, University of Leuven, Belgium

**I. Scharrer**

Johannes Gutenberg-Universität Mainz, Germany

**W. Schramm**

Ludwig-Maximilian-Universität, Germany

**J. van der Bom**

Leiden University Medical Centre, The Netherlands

**H. Verbruggen**

Central Haematology Lab, UMC St Radboud, The Netherlands

### REPRESENTATIVES FROM ACADEMIA

**A. Gringeri**

A. Bianchi Bonomi Centre, Italy

**W. van Heerde**

Central Laboratory for Haematology, Radboud University Nijmegen Medical Centre, The Netherlands

## **EXPERTS FROM ISTH**

**K. Mertens** - Chair of ISTH SSC for FVIII and FIX  
Utrecht Institute for Pharmaceutical Sciences, The Netherlands

## **BPWP MEMBERS, EXPERTS AND OBSERVERS**

**M. Haase** – BPWP Chairman  
Paul-Ehrlich Institut, Germany

**D. Apele-Freimane**  
Zāļu valsts aģentūra, Latvia

**N. Calvente Cestafe**  
Agencia Española del Medicamento y Productos Sanitarios, Spain

**E. Fabbri**  
Agenzia Italiana del Farmaco, Italy

**C. Falção**  
Hospital Garcia de Orta Pragal, Portugal

**B. Flores**  
Medicines and Healthcare products Regulatory Agency, United Kingdom

**L. Gaydarova**  
Bulgarian Drug Agency

**A. Hilger**  
Paul-Ehrlich Institut, Germany

**P. Laitinen-Parkkonen**  
Lääkelaitos, Finland

**B. Ljungberg**  
Läkemedelsverket, Sweden

**E. Mavrokordatou**  
Ministry of Health, Cyprus

**C. Rasmussen**  
Lægemiddelstyrelsen, Denmark

**C. Ratignier**  
Agence Française de Sécurité Sanitaire des Produits de Santé, France

**R. Seitz**  
Paul-Ehrlich Institut, Germany

**M. van den Berg**  
Creveldkliniek, Utrecht University Medical Centre, The Netherlands

## **CHMP, PhVWP, BMWP, PAEDIATRICS WP MEMBERS AND OTHER EMEA EXPERTS**

### **J. Dodt**

Paul-Ehrlich Institut, Germany

### **B. Keller-Stanislawski**

Paul-Ehrlich Institut, Germany

### **C. Kreft-Jais**

Agence Française de Sécurité Sanitaire des Produits de Santé, France

### **D. Mentzer**

Paul-Ehrlich Institut, Germany

### **F. Rotblat**

Medicines and Healthcare products Regulatory Agency, United Kingdom

### **C. Schneider**

Paul-Ehrlich Institut, Germany

### **D. Stenver**

Lægemiddelstyrelsen, Denmark

### **R. Thorpe**

National Institute for Biological Standards and Control, United Kingdom

### **M. van der Plas**

Rijksinstituut voor Volksgezondheid en Milieu, The Netherlands

## **REPRESENTATIVES FROM EU AUTHORITIES**

### **N. Grené-Lerouge**

Agence Française de Sécurité Sanitaire des Produits de Santé, France

### **M. Hoefnagel**

Rijksinstituut voor Volksgezondheid en Milieu, The Netherlands

### **N. Prieto Santos**

Agencia Española del Medicamento, Spain

## **REPRESENTATIVES FROM EUROPEAN HAEMOPHILIA CONSORTIUM / WORLD FEDERATION FOR HAEMOPHILIA**

### **P. Giangrande**

World Federation for Haemophilia (WFH), Oxford Haemophilia Centre, United Kingdom

### **H. Hartl**

European Haemophilia Consortium (EHC), Austria

### **B. O'Mahoney**

World Federation for Haemophilia (WFH)

### **U. Schlenkrich**

European Haemophilia Consortium (EHC), Germany

## REPRESENTATIVES FROM OTHER AUTHORITIES

### **C. Legare**

Health Canada

### **J. Lozier**

Food and Drug Administration, United States

### **C. Miller**

Centers for Disease Control and Prevention, United States

### **H. Momose**

National Institute of Infectious Disease, Japan

### **K. Nomura**

Pharmaceutical and Medical Devices Agency, Japan

### **A. Padilla**

World Health Organization, Switzerland

### **M. Soucie**

Centers for Disease Control and Prevention, United States

### **K. Yamaguchi**

National Institute of Infectious Disease, Japan

## INDUSTRY REPRESENTATIVES

### **N. Bajwa**

Bayer

### **E. Bastida**

PPTA Industry (Grifols)

### **F. Bridey**

IPFA Industry (LFB)

### **C. Dash**

IPFA Industry (Bio Products Laboratory, UK)

### **H. Ehrlich**

Baxter

### **T. Evers**

International Plasma Fractionation Association (IPFA), The Netherlands

### **B. Ewenstein**

Baxter

### **J. M. Feingold**

Wyeth

### **K. Furuya**

IPFA Industry (Japanese Red Cross, Japan)

### **E. Gorina**

Bayer

### **S. Guazzini**

PPTA Industry (Kedron S.p.A.)

### **M. Gustafson**

Plasma Protein Therapeutics Association (PPTA), Belgium

### **J. Lee**

IPFA Industry (Bio Products Laboratory, UK)

## **INDUSTRY REPRESENTATIVES (continues)**

**G. Lemm**

Bayer

**J. Lindner**

PPTA Industry (Biotest AG)

**S. Renlund**

Biovitrum AB, Sweden

**F. Rossi**

IPFA Industry (LFB)

**D. A. Roth**

Wyeth

**T. Steinbach**

Wyeth

**P. Strengers**

IPFA Industry (Sanquin)

**T. Suiter**

PPTA Industry (ZLB Behring)

**L. von Bonsdorff**

IPFA Industry (Sanquin)

**I. von Hoegen**

Plasma Protein Therapeutics Association (PPTA), Belgium

**C. Waller**

Plasma Protein Therapeutics Association (PPTA), Belgium

**O. Walter**

PPTA Industry (Octapharma)

**J. Weber**

Bayer

## **EMEA SECRETARIAT**

**B. Neugebauer**

**C. Draï**

**K. Balzan**

**S. Blackburn**

**J. Childs**

**S. Domingo**

**X. Kurz**

**G. Silvester**

**P. Tsintis**

**L. Svobodova**